Project Overview

Business Plan without Funding Numbers March 1, 2019 Quantum Leap Companies The Quantum Leap companies represent a family of technology companies fully owned by the Quantum Leap Holdings parent company with focus on both horizontal big data analytics opportunities as well as unique, vertical opportunities in high growth segments such as biomedicine, healthcare and the internet of things. In each segment a unique, highly competitive combination of big data analytics software and proprietary hardware platform is combined. The key to all offerings is best of breed solutions and products at an affordable pricing that will disrupt both horizontal and vertical markets in a major way. To put it simply, Quantum Leap is technology for humanity. Quantum Leap’s products empower those that use them. 2 General Use of Proceeds 14 Markets and Opportunity Quantum Leap Analytics: Quantum Leap distinguished itself on the cutting edge of Big Data Analytics after Joseph’s early work in Artificial Intelligence (AI) and analytical software innovations for DuPont, Tyco, Boeing and Ford. ∙ Since its inception in 1999, the Company has generated in excess of $50 million in US Government R&D revenues through its consulting to DARPA (US Department of Defense), HSARPA (US Department of Homeland Security), IARPA (CIA), US Office of Naval Research and the US Air Force Research Laboratory. ∙ The Company holds more than two dozen patents and patents pending. The patents cover all three foundational areas of advanced analytics (Descriptive, Predictive and Prescriptive) as well as eCommerce, Crowd Sales and Social Networks. The Company’s products uniquely encapsulate the complexity of data sciences, providing end users with simple tools to quickly and automatically detect informative patterns hiding in the labyrinth of data. QLI is the only company which has the experience, patents and software covering the entire spectrum of advanced analytics. QLI goes beyond what others do with analytics software, and has taken their models a step further and developed predictive and prescriptive analytics which allow the user to identify what will happen as well as actively influence the desired outcome. ∙ Current clients include Mylan Pharmaceuticals, City of Hope National Medical Center, Greater New York Hospital Association, NYU Langone Medical Center, New York City Government and the Office of Naval Research (ONR) 15 QLI is ready to enter the mainstream market by pivoting the business model from the US Government market R&D to Big Data Analytics commercial software-as-a-service market. This will significantly increase gross margins from 6% for one-time R&D projects to a market segment that offers greater than 80% gross margins from monthly revenue sharing, annual and multi-year subscriptions, support and professional services. Quantum Leap Innovations® has two mature, proprietary software products: Quantum Leap® Analyst and Quantum Leap® Buzz. These products will join the fast growing (18% CAGR through 2019), multi billion (estimated to reach $7B by 2019) Big Data Analytics market space, expanding towards cloud delivery and mobile consumption modes within 6 to 12 months post-funding. Quantum Leap ® Analyst Quantum Leap® Buzz Identifies patterns in: Structured Data Unstructured Data Cloud based social media (i.e. Twitter) Initial Primary Target Data intensive industries Trend based industries Demographic Life Sciences Advertising Telecommunications Marketing Healthcare Media Energy Retail Banking Compliance Financial Benefits Identifies patterns and trends Aggregates patterns from social via a patented machine learning networks - provides "situational technology (without a human awareness" parameter input) Patterns form the basis for Predictive Handles any domain without models developed and built special domain knowledge or automatically in Analyst semantics Requires no implementation, Can easily be modified to customization or training support any word-based language Can be used by non statisticians Can be used by non statisticians Alert Dashboards allow the user to specify which events warrant an email text message 16 The proceeds of this financing will be used to fund growth initiatives in the commercial market. Key areas of expansion will focus on client support, sales and development. ∙ Expand commercial offerings of Quantum Leap® Analyst ∙ Support successful commercial launch of Quantum Leap® Buzz ∙ Expand the programs for broader healthcare related analysis ∙ Expand product offerings ∙ Commercialize the patent portfolio Quantum Leap Analytics’ Products: Quantum Leap Analyst, Personal Edition The Personal Edition is a single-user version of the Analyst for use either on a desktop or notebook computer, or to be potentially virtualized in a private cloud. It is designed to work with structured data that is imported from Excel, text files, or from an SQL table. The software relies on data presented in tabular format, and a proprietary in-memory caching technique will enable users to process and analyze tables with up to several million records and several hundred columns – even on a laptop. Quantum Leap Analyst, Big Data Edition The Big Data Edition is a single-user version of the Analyst, which is extended by using the Apache Spark processing engine to be able to deal with larger data tables (infinite in theory) by distributing the in memory storage and analytics on a cluster of machines. Quantum Leap Analyst, Enterprise Edition The Enterprise Edition extends the scope of the Personal Edition and the Big Data Edition by supporting multiple users and allowing them to share data, patterns, and models for collaboration. The Enterprise Edition also includes a Data Harmonization capability (the ability to visually specify and execute the workflow for integration and transformation of data from multiple data sources), and a Mashboard capability (the ability to easily create dash boards for monitoring and visualizing changes in patterns and data over time). Quantum Leap Buzz, Personal Edition The Personal Edition of the Quantum Leap Buzz analyses unstructured data. The Buzz allows a single user to connect to preset Social Streams (e.g. Twitter, Facebook, Instagram, Snapchat, etc.), find Patterns, and organize the content by Topics and Themes. It will be available via a browser on any computer for paid subscription to the Buzz public cloud site. 17 Quantum Leap Buzz, Enterprise Edition The Personal Edition of Quantum Leap Buzz is extended to support multiple users which allow them to share Data, Content, and Patterns for collaboration. The Enterprise Edition also includes the ability to define and scrape data from custom-defined Data Streams (e.g. institutional web sites, newspapers, blogs, forums, etc.) and harmonize them with the preset Social Streams to be able to develop and utilize new Patterns. The Enterprise Edition of the Buzz will also include a Mashboard capability (the ability to easily create dash boards for monitoring and visualizing important topics and themes over time in terms of e.g. sentiment, social media interest and involvement). The Mashboard feature will also enable the user to “push” newly discovered Patterns to enterprise subscribers’ digital devices (computers, phones, etc.) based on pre-defined Topics and Themes of interest, at pre-defined (or as developed) time intervals. Quantum Leap Fusion, Enterprise Platform The Quantum Leap Fusion Platform combines the Enterprise Editions of Quantum Leap Analyst and Quantum Leap Buzz to unify structured and unstructured data, as well as support multiple users. Fusion includes all of the capabilities of the Enterprise Editions of both the Analyst and the Buzz. Quantum Leap Analyst, Advanced Edition for Big Data or Enterprise Editions The Advanced Edition of Quantum Leap Analyst will incorporate automatic modeling, simulation and optimization technologies for prescriptive analytics and active decision-making. Duly noted, prior to entering into the field of pattern based analytics for structured and unstructured data, Quantum Leap Innovations, Inc. spent the better part of 15 years working closely with US government agencies to develop sophisticated modeling, simulation and optimization technologies. That is Quantum Leap Innovations’ legacy and the patents and the software that was produced under a series of contracts with the government are part of the intellectual property of Quantum Leap Innovations. 18 Quantum Leap Bio: Company Synopsis Quantum Leap Bio is a private company to be incorporated in 2015 as a wholly owned subsidiary of Quantum Leap Holdings, Inc. Our company has a powerful genomics platform technology that offers several key competitive advantages over the microarray technologies currently marketed by genomics industry leaders. Unlike the microarrays, our platform, called the GeneSystem320™or GS320™can detect unknown genes as well as novel variants of already characterized genes and can do so for significantly less cost and with better sensitivity and higher quality data. This uniquely positions Quantum Leap Bio to compete in the $4 billion plus genomics market. Further, we have combined our high-powered genomics platform with a proprietary immunology platform called the ImmunoMouse™that allows for the generation of antibodies directly from target sequences produced by our genome screens. This gives Quantum Leap Bio the ability to find new genetic targets, then, quickly and cheaply, make antibodies against these targets. These antibodies can then be used to validate the target and to make diagnostic tests and therapeutic monoclonal antibodies. We are the only competitor that can seamlessly go from sample to target to antibody to therapeutic or diagnostic in one short and cost-effective timeline. Preparation of Antibodies Discovery of Genes ImmunoMouse GeneSystem320 The Discover- to-Product Process at Quantum Leap Bio Mission Statement Antibody-based Therapeutics & Diagnostic Biomarkers Quantum Leap Bio intends to commercialize its best-in-class genomics platform and antibody services. The company intends to exploit its core technologies to discover, validate and develop new biomarkers for the treatment and diagnosis of cancer. 19 Core Technologies ∙ GeneSystem320™ (GS320™): a revolutionary genomic discovery engine and gene expression analysis platform for the discovery of new genes (both known and unknown) and for the analytical study of gene expression patterns, whether human, animal, or other. The GS320TM offers multiple competitive advantages and can be used instead of or along side of current technologies such as the GeneChip™ platform of Affymetrix and the BeadChipTM platform of Illumina. ∙ ImmunoMouse™: for the rapid conversion of genomic information directly into antibodies. ImmunoMouseTM allows the generation of specific antibodies directly against genetic sequences of biological and clinical significance without requiring the time consuming and costly preparation of the traditional protein immunogen or pre-processing of sera to monoclonal antibodies. Initial objective: revenue production!! The company’s initial objective is to insure financial stability and profitability by producing revenues. We intend to do this by launching the GS320™, which is commercial ready, into the $4 billion genomics market. The GeneSystem 320 The GS320™comes as a kit that allows researchers to determine changes in gene expression levels and patterns that are the difference between normal tissue and diseased tissue. The GS320™can enable 20 researchers to find the few key genes out of the tens of thousands of genes in the human genome that are responsible for the onset and progression of diseases such as cancer and AIDS. Further, the GS320™ allows researchers to experimentally determine the effects of attacking a target gene on the rest of the key genes in a disease. No other technology can do this as well as the GeneSystem320™can! The Genomics Market The dominant segments in the genomics market are sequencing, which tells you the order and type of each DNA base pair in a gene of interest, and gene expression analysis, which tells you how genes are over or under expressed in a disease. Gene expression analysis can be determined in multiple ways, but the leading method is microarray technology. This technology, introduced over a decade ago, makes use of thousands of copies of probes for different genes fixed onto a surface such as a glass microscope slide (called a microarray chip) or glass bead. Researchers can add genetic material they extract from samples of disease tissue to these microarrays to get an idea of the levels of expression of genes they are interested in. This technology is very costly, prone to false positives and limited to only those genes that are already characterized, but it does allow for screening against thousands of genes at a time. Market leaders in microarray sales are Illumina (Nasdaq ILMN), Affymetrix (Nasdaq AFFX) and Agilent (NYSE ticker A). The primary users of genomics products are the pharmaceutical and biotechnology companies and government and academic research labs. We estimate these users spend over $4 billion each year on genomics research and that number is expected to grow to $5 billion. Genomics has become a primary tool for finding new drugs and diagnostic markers as well as a driving force behind personalized medicine. A key factor in determining how much the pharmaceutical industry spends each year on genomics has been the need to replace revenues lost as drugs become generic. These lost revenues can be large, as in the recent case of Pfizer’s cholesterol lowering drug Lipitor, which delivered over $130 billion in revenues before going generic. The need to replace older drugs with newer ones has been constant over the past decade, but is expected to dramatically increase over the next few years. According to EvaluatePharma, an unprecedented set of patent expirations will hit drug makers in 2015 as drugs with annual sales of $250 billion will face generic competition. This is known as the “patent cliff” and could greatly increase the genomics market. 21 The “Patent Cliff” Quantum Leap Bio’s Marketing Strategy for the GS320™ ∙ The company intends to avoid direct competition with market leaders by focusing on underserved niches within the genomics market and emphasizing the compatibility of its platform technologies with products and services offered by the leaders. The competitive advantages of the GS320™: ∙ Open architecture. Current gene chips provide data only from genes that have already been sequenced. The GS320™can provide data from the entire transcriptome, including not yet characterized genes and gene variants. ∙ Cost effectiveness. We estimate the GS320™can be run for less than 50% of the cost of currently available gene chips. ∙ Higher flexibility. The GS320™is suited to better serve the lower to mid volume and complexity users than the gene chips and does not require an investment in additional instrumentation, software or reagents. ∙ Longer probe length. Current gene chips are limited by their chemistry to probe lengths of 25 to 50 base pairs, which limits the sensitivity of the analysis and requires greater copy numbers per chip to compensate. The GS320™average probe length is 128 base pairs. The main reason why Affymetrix lost market leadership to Illumina is attributed to longer probe length (50 base pairs vs. 25 base pairs). ∙ Rapid validation of genomic analysis is achievable by coupling with the ImmunoMouse technology. 22 ∙ GS320™data is reproducible and real-time confirmable. Samples can be archived. ∙ The GS320™is not species limited. Current gene chips must be designed individually for each species and only a few species are available. The GS320™can be used across all species above the bacterial level. Validating Data Data from both internal and external studies have shown that the GS320TM can detect previously unknown genes and gene variants in multiple models. The company believes it can replicate this feat in our Ovarian Cancer Transcriptome Project, resulting in multiple potential new patentable therapeutic and diagnostic targets. Breast Cancer: We have developed a gene expression assay for invasive breast cancer based on expression patterns of nine genes, six of which were previously unknown and only three were detectable using the Affymetrix Gene Chip. These unique genes were found after screening only 0.94% of the breast cancer transcriptome. Selected Genes Associated With Breast Cancer Gene Gene Expression as seen in GS320 Confirmed with RT -PCR Type of protein On Affymetrix GeneChip? CGI-1 6 X up -regulated Yes Cytoplasmic Yes CGI-2 5X up -regulated Yes Transmembrane No CGI-3 2 X up -regulated Yes Cyto or nuclear No CGI-4 2 X up -regulated Yes Cytoplasmic No CGI-5 3 X Down regulated Yes Many transmembrane doma ins No CGI-6 3 X up -regulated Yes Transmembrane Channel protein Yes CGI-7 2 X up -regulated Yes and Northern Cytoplasmic Yes CGI-8 3 X up -regulated Yes Cytoplasmic No CGI-9 4X up -regulated Yes Channel protein No Scizophrenia: The National Institute of Mental Health (NIMH) undertook a large, comparative study to screen monkeys for known genes associated with schizophrenia. They chose the GS320TM as the primary gene screening tool. The GS320TM found multiple new and uncharacterized variants of key genes, despite the monkey genome having already been sequenced. The study planned to use Real Time (RT) PCR as a check on the results from the GS320TM, but found the GS320TM to be so superior that the RT-PCR arm was dropped. 23 Gene Variants Variants Not Variants Gene Detected with GS320 In NIMH Gene Database Detected by RT-PCR GAD1 6 4 2 DISC1 4 2 1 NRG1 16 7 N/D CAPON 2 1 N/D CHRNA7 2 1 N/D PPP1R1B 4 2 N/D EGFR 6 2 N/D ErbB4 4 3 N/D IGF-1 3 1 N/D IGF1R 2 1 N/D NIMH Schizophrenia gene screen: The GS320 finds undiscovered variants The ImmunoMouseTM– a Leap Forward for Antibodies The ImmunoMouseTM represents an important leap forward in the preparation and production of antibodies for research, diagnostic and therapeutic uses. The ImmunoMouse™allows researchers to go directly from discovery of a gene to production of specific antibodies at a fraction of the cost and in a fraction of the time necessary for conventional immunization methods. 24 Identify novel Identify novel gene gene ImmunoMouse Current Method TM ImmunoMouse Current Method TM Insert gene in immunization plasmid Insert gene in immunization plasmid Immunize mouse Immunize mouse Host animal produces protein in vivoHost animal produces protein in vivo Antibodies in 3-7 weeks Antibodies in 3-7 weeks The ImmunoMouse Process Benefits of the ImmunoMouse™: Insert gene in expression plasmid Insert gene in expression plasmid Ove -express protein in host system Ove -express protein in host system Purify protein & validate Purify protein & validate Immunize Mouse Immunize Mouse Antibodies in 10 -18 months Antibodies in 10 -18 months ⮚ Conventional immunization requires large amounts of purified protein, ImmunoMouseTM requires none. ⮚ Conventional immunization takes months to produce antibodies, ImmunoMouseTM takes 3-7 weeks. ⮚ New targets defined by gene screening must be validated by in vitro and in vivo studies that often require the generation of monoclonal antibodies against the target. Antibodies generated by ImmunoMouse can be used to validate the target WITHOUT generating monoclonals, saving millions of dollars and months of development time and reducing the false positives. ⮚ ImmunoMouse™antibodies can be used directly as research tools or diagnostic antibodies and can quickly be transformed into monoclonal versions for therapeutic use. ⮚ ImmunoMouseTM antibodies are high titer, high grade. Quantum Leap Bio used ImmunoMouseTM to make antibodies against a well-documented “problem” antigen, CD-19. FACS analysis (Fluorescent-Activated Cell Sorting) shows a non-immune (negative control), a commercially available monoclonal antibody (positive control), conventional immunizations and ImmunoMouseTM (bottom, right). The farther to the right the peak is, the better the antibody. Results show the ImmunoMouse™ makes high titer, superior grade antibodies even against difficult targets. 25 FACS Analysis of ImmunoMouse: We Make Better Antibodies Longer term objectives: licensing revenue and developing new drugs The GS320™has been successfully utilized both internally and by external collaborators to find new biomarkers and new variants of known genes in breast cancer, prostate cancer and schizophrenia. The company believes that it can generate multiple new targets for therapeutics and diagnostics over the next three years of operations and we intend to license the majority of these. Quantum Leap Bio has planned research projects that could generate these targets, foremost is our ovarian cancer transcriptome project. The Transcriptome Project The project is to map the expression patterns of ALL actively transcribed genes in a human cancer model. This is a never-before-done feat that would provide significant publicity for our platform technologies, increasing the demand and subsequent sales for our products, increasing the interest and valuation of prospective licensing options and providing numerous targets, both diagnostic and therapeutic, for either development or license. Further, substantial intellectual property would be generated around new genes and gene variants that is not possible using current technologies. 26 We have chosen Ovarian Cancer as our target as: ⮚ it is a large market, with >21,500 new cases diagnosed per year in the U.S. alone ⮚ there are internal comparators between platinum sensitive, platinum insensitive and normal tissues ⮚ good access to tissue ⮚ no new treatments ⮚ no good biomarkers ⮚ a high probability of multiple new targets The company plans to complete the mapping of expression patterns of every active gene in the entire ovarian cancer transcriptome, a feat we can accomplish in twelve months or less after securing financing. We believe this project could establish Quantum Leap Bio as the world’s premier biomarker discovery and validation competitor. The publicity generated by this accomplishment could dramatically increase sales of our GS320™kits and provide a basis for premier pricing should the company license this technology. In addition, this project could provide a virtually unlimited number of partnerable biomarkers for both diagnostic and therapeutic uses as well as significant and valuable intellectual property. The company plans to license selected diagnostic targets while retaining the rights to the most promising therapeutic candidates and developing these to create sustainable, long-term value for its shareholders. Summary Quantum Leap Bio provides a unique investment opportunity in a company with a ground-breaking genomics platform technology that is commercial ready and could generate recurring revenues sufficient to achieve profitability within the next three years. The combination of the GS320™’s abilities to discover previously unknown genes and our immunology platform (the ImmunoMouse™) gives Quantum Leap Bio the unique capacity to discover and validate novel biomarkers in greater number, less time and for less cost than any other competitor. These biomarkers can be licensed to generate significant non-dilutive revenue or selectively retained and developed to create a portfolio of new drugs in multi-billion dollar markets like cancer. 27 Quantum Leap Defense: Quantum Leap Defense is engaged in the sales, marketing and distribution of a supply chain management and container security device within the maritime industry. The Company has developed a deployment-ready device and intends to promote, distribute and market its proprietary Advanced Container Security Device (ACSD), known as the Container Automated Monitoring System (CAMS). GateKeeper’s CAMS will provide real time visibility and proactive supply chain management of goods in transit especially for vulnerable merchandize such as bulk medicaments, pharmaceuticals, foods, perishable goods, and agricultural products; fully comply with the US government’s Container Security Initiative (CSI) mandate, while simultaneously assisting in the prevention and immediate reporting of theft, intrusions, loss, presence of weapon(s) of mass destruction, and acts of potential terrorism. Our business goals for the year 2015-2016 are as follows: ⮚ Capitalize the Company to achieve its growth objectives ⮚ Launch our CAMS product(s) ⮚ Implement our marketing and sales plan Develop related products with our licensed technology The Product (CAMS) While CAMS is, and may appear to be a premium device, it is configured for quick payback on the customer’s ROI and will become the standard for the future, just as cell phones and microcomputers have become ubiquitous and replaced computer mainframes and some Personal Computers. Our key product into the supply chain management and security industry is a proprietary Advanced Container Security Device (ACSD) known as “CAMS” (Container Automated Monitoring System). The Company is currently concentrating primarily on commercially launching CAMS for maritime cargo CAMS device size: (3 ¼” x 5” x ½”) containers because since 9/11, the maritime segment of the container security market is being heavily encouraged and supported by governmental agencies of the USA and other major governments/countries, by shippers of goods, by port authorities, by manufacturers and importers of goods, and by insurance and bonding companies to enhance their security systems. CAMS was developed as the only viable solution to meet and exceed the NEW US governmental requirements (CSI) for 100% screening of maritime shipping containers entering US ports and to serve future security needs, while performing as an efficient and dynamic supply chain management device for goods in transit. Furthermore, CAMS is also suitable for other applications such as air cargo containers, berths, holds of ships and airplanes, as well as the trucking and rail industries, making it an 28 ideal product to quickly penetrate other market opportunities. CAMS is fully developed, ready now, has been successfully field-tested and 3rd party validated. CAMS is an affordable, multi-purpose security and supply chain management device to be affixed inside each individual shipping container, which combines various functions including being an intrusion detector, a geo-locator, a detection sensor of invasive and undesirable materials, a supply chain monitor especially for vulnerable products, and a communication device. CAMS multiple functions provide the following USES and BENEFITS 1) Effective and proactive supply chain management device; provides real time visibility and reporting in a dynamic environment; well suited for bulk medicaments, pharmaceuticals, perishable goods, foods, agricultural, and high value retail products sensitive to contamination, spoilage, breakage, and pilferage. a) Device-specific temperature/barometric pressure; GPS, intrusion detection, over-air programming, and other specifications for security and supply chain management allow customer special requirements to be achieved through CAMS’ over-the-air programmable dynamic interface already inherent in the CAMS product; b) Communicates warning at every point of its container’s voyage, any attempted theft and/or adulteration of container goods; container intrusions through any area of the container (competitors usually monitor doors only); or changes in the cargo, as directed by customer specified monitoring settings to report warnings on spoilage, contamination, temperature and humidity changes, water damage to packaging, leakage, and/or breakage inside the shipping container; c) Detects atmospheric changes, variations in temperature as well as the presence of bacterial contamination, gives the CAMS device a significant advantage in cold supply chain management; d) Detects in minute quantities, narcotic drugs and other dangerous, illegal, and unwanted substances including insects, agricultural hazards, and the presence of human trafficking; provides a significant advantage to Customs, Immigration, and other law enforcement; e) Monitoring 24x7, in accordance with customer specifications, the location, contents, and security of the container from product load and all the way through to final destination and transmits its encrypted and anti-tamper signals in real time, worldwide, over the strongest available frequency. 29 2) Detects and reports in real time: a) Presence of Weapons of Mass Destruction; CBRNE (Chemical, Biological, Radiological, Nuclear, Explosive) in minute quantities (nanograms) either in solid/liquid/gaseous states, including, but not limited to: i) Minute trace quantities of the hard to detect PETN, a powerful explosive used by the shoe bomber and other terrorists (http://www.guardian.co.uk/world/2009/dec/27/petn pentaerythritol-trinitrate-explosive), can be detected by CAMS utilizing a much smaller footprint and offering superior detection capabilities to the failed “puffer machines” and security swabs used to look for trace amounts of certain substances. ii) CAMS superior detection of radioactive or nuclear materials does not require the use of Helium 3; an advantage over competitors who use this antiquated method of detection which is dependent on the limited supply of Helium 3, a crucial raw material for the screening machines that were to be utilized in shipping ports for the detection of plutonium, uranium, and nuclear weapons. 3) Performs “geo-fencing” which sets the initial baseline of the empty container, scanning and recording every change until all the contents are completely loaded and the door is closed/sealed, thus validating and securing its electronic manifest. 4) CAMS communications are “self-reliant” as well as “mesh network” with each other so that CAMS equipped containers are not hampered by their location on the ship and these capabilities are useful for emergencies, increase battery life, and assist in anti-tamper and anti-jamming functions. 5) CAMS is designed with highest level encrypted transmissions which cannot be detected or intercepted and with anti-tamper self-protection detection which when dropped in hostile locations such as Afghanistan, will prevent any reverse-engineering of the intellectual property through a combination of hardware and software firewalls and a self-destruct mechanism that prevents forensics after the device has communicated its information. 6) Streaming video monitoring (color, black & white, hi or low resolution) that can identify an intruder at the user desired level of resolution in as little as eight frames of captured video, can be added as an additional function to the CAMS if so desired by the customer. 30 7) Provides greater than full CSI compliance for 100% container screening and acts as “CSI EZPASS” which makes the shipping container port-independent, facilitating speed of transport from point of origin to final destination without requiring the container to be screened at either port of origin or port of entry, thus reducing port congestions and eliminating additional port-related expenses for the shipper. 8) Provides customer 24x7 visibility and assurance reporting of each individual shipping container from point of origin through its entire voyage to final destination, thus ensuring end to end security and product quality through secured, efficient, and free movement of global commerce. CAMS Features and Key Technology Advantages CAMS technology is truly above current state of the art and sets a new paradigm for what DHS has defined as an Advanced Container Security Device (ACSD). 1) No other product on the market combines device-specific temperature/barometric pressure; GPS, intrusion detection, over-air programming, and other specifications for security and supply chain management, along with superior detection of Weapons of Mass Destruction (CBRNE), illicit substances, narcotics, and other undesirables, requiring only minute (nanogram) quantities in either solid/liquid/gaseous states. 2) No other product on the market performs “geo-fencing” which self-records and reports container content from baseline of empty until all the contents are loaded and the door is closed/sealed, thus validating and securing its electronic manifest. Programmable in various dimensions and can be effectively disguised. 3) Highest level encrypted transmissions which cannot be detected or intercepted; the initial, preliminary protection layer is designed to meet “the requirements of FIPS 140-2, Level 4, the most secure active perimeter protection.” 4) Proprietary algorithm allows unique transmissions that provide better security and more available data than RFID or cellular- based communications devices currently in the market. Encrypted and anti-tamper signals are transmitted in real time, worldwide, over the strongest available frequency. 5) CAMS units are protected by a secure, proprietary, “GateKeeper” enclosure that will self-destruct the internal contents to ensure that no material or information will be available for any forensic recovery. Any attempt or actual breach would be immediately reported, as programmed, prior to 31 destruction. This includes designed electronic monitoring, probing and, or reverse engineering attacks. 6) Containers equipped with CAMS are not hampered by their location on the ship as CAMS units are intelligent devices that “mesh network” with each other, and can communicate on various U.S. and International frequencies and signal strengths and other proprietary communication methods. This also serves as a redundancy in emergency situations. 7) Substantial battery life, which (under normal usage) exceeds the average life of a maritime shipping container (approximately 7 years). 8) Device footprint is arguably one of the smallest in the industry (3 ¼” x 5” x ½”); approximate size of a small cell phone which can be installed either covertly or overtly, inside the shipping container. CAMS - Value Proposition (Value to Customer/User) The ultimate individual Supply Chain Management Device and “International Police Surveillance Force in-a-can +”. Fully CSI compliant; facilitates the secure and free movement of global commerce and reduces customer costs and losses. Annual Maritime Container Shipment Losses exceed $105 Billion (Retail=$50B, Agriculture=$35B, Pharmaceuticals=$20B) We know these losses could be significantly reduced with the use of Quantum Leap’s CAMS. This plus other benefits to the Retail Industry (significant improvement in supply chain management) will be derived from: ∙ Fewer delayed and misrouted shipments ∙ Better container and terminal efficiency; reduces port congestions ∙ Reduced inventories; improved just-in-time reliability ∙ Reduced theft and lower insurance costs ∙ Assurance of 24x7 monitored product quality and preservation, essential for vulnerable goods ∙ Reduced vulnerability to maritime shipping container-borne terror attack ∙ Secured and monitored shipping from product load to final destination ∙ CSI Compliance – EZ Pass – saving time and costs to market 32 ∙ Facilitates efficiency and management of container utilization ∙ Cost savings, cost avoidance, and cost containment both to the owner and the user ∙ For owners of leased containers, CAMS becomes a new revenue stream ∙ CAMS ROI to owner can be realized within a few trips and is a competitive advantage ∙ Container owner capability to participate in C-TPAT (Customs-Trade Partnership Against Terrorism) ∙ Aids in capability to detect human trafficking; presence of illicit substances in both active and idle containers CURRENTLY, the owner of maritime shipping containers just pass on all shipping costs+ to the user, which include all fees as well as screening fees at CSI compliant ports, and maritime shipping container owners and lessors are not making money on screening fees and other fees. The ROI for the initial cost of CAMS to a maritime shipping container owner or lessor could be realized within 5-10 trips for same maritime shipping container and for the life cycle of the maritime shipping container, it will become a cost-savings with added bonuses and would be a competitive advantage to the maritime shipping container owner and lessor. Once CAMS reputation is established, it is foreseen that some shipping fees will be eliminated (i.e., screening at ports) and insurance companies could potentially lower premiums for CAMS-equipped containers, thus passing on savings to the maritime shipping container owner and the end user. The investment payback to the maritime shipping container owner can be amortized over time and still continue to pass it on to the user until the break-even point or have a new source of revenue with only incremental cost being passed on to the end user once complete investment payback is reached. Therefore, the ROI to maritime shipping container owners and lessors can exceed the initial investment cost of CAMS, plus provide them a competitive advantage to capture additional business from maritime shipping container owners that do not offer CAMS. Also as the retail industry looks to improve their supply chain management and be proactive, they will demand that CAMS be installed in maritime shipping containers they use for shipping. CAMS - Intellectual Property 33 All of “CAMS” technology is proprietary and exclusively licensed, on a worldwide basis. Effectively all the incorporated technology exclusively licensed to GateKeeper is proprietary in nature and can attribute their “Genesis” in various sectors over several years. A variety of proven and tested detection methods and technologies such as those used to successfully detect and identify the specific offending vessel in a Great Lakes bilge spill and prosecute same is one of the first such cases for the predecessor of the EPA. Another was used on the first two Viking Mars Lander Projects. These are just a few of several tested and proven technologies incorporated within CAMS. Market Size – for CAMS CAMS: The ultimate individual Supply Chain Management Device and “International Police Surveillance Force in-a-can +”, addressing a 36 Million active maritime fleet unit container market with a potential global market size of over $50 Billion. The total potential market is 108 million existing maritime containers, with an annual growth rate of 10%. At this time however, Quantum Leap plans to focus on initially reaching the active fleet unit container market, which is about 33% of the existing total market. This niche is initially estimated to be 36 million maritime cargo containers at $1,500 per CAMS system ($50 billion dollars). The 36 million cargo containers represent estimated size of the active Fleet. (source: Containerisation International, World Container Census 2010). The Market is easily greater than $50,000,000,000 ($50B) annually with the number of cargo containers utilized each year growing by 10%+ and in that each year, 5% of the cargo containers are replaced due to physical conditions, damage, retirement, and other circumstances. Within the users of maritime shipping containers, there are numerous businesses and governments which are interested in CAMS and can use most, if not all of the applications provided by CAMS. Our initial target market is ALL maritime shipping containers which need to comply with the Rotterdam Rules and US Homeland Security requirements as well as ALL domestic shipments for security and perishable goods proactive management. The maritime container industry is staggering. Seaports throughout the world are critical gateway locations for the movement of international commerce and the world’s most common means of mass goods transport is through the use of maritime shipping containers. These containers account for 95% of U.S. import-export shipboard cargo. According to Department of Homeland Security, there are more 34 than 108 million containers worldwide. It is estimated that there are approximately 200 million shipboard trips annually among seaports around the world. Sales and Marketing Sales and Marketing Activities – The Company will implement certain media advertising and expand our marketing activities to promote our products and create a favorable Quantum Leap brand image. The Company’s initial focus will be on providing CAMS for the shipment of high net worth items (specifically rare and high market value collectibles, art, antiquities, artifacts, etc.); consumables which can spoil (frozen foods, flowers, fruits, vegetables, plants, agricultural products, etc.); merchandize which can become contaminated (bulk medicaments, pharmaceuticals, foods, chemicals, etc.) and items which could be harmful to the public (radioactive materials, biohazard materials, explosives, etc.). We will also participate in leading industry trade shows, conventions, and similar events to attract and secure customers for our security and supply chain management products. Target Market Segments: Source: Container Supply Review World Shipping Council, May 2011; TAL Annual Report 2010 The primary market segments are Maritime Shipping Companies, Freight Companies, Container Manufacturers (new containers), and Governments. Currently, existing cargo containers represent almost 87% of the Market Segment and new and replacement containers will account for approximately 14%. 35 Those that benefit the most from CAMS are major retailers, exporters to the US, and wholesalers who are the primary users and own or lease these shipping containers. As such, they are considered sub categories of GateKeeper’s primary market segment. However, the primary market segments (non-user owners of containers) likewise benefit from CAMS as a new revenue stream because after they pass on the amortization of the initial cost to the container user, they can still continue to pass on the “amortization” value as a new revenue stream, previously unavailable to the container owner. For the container owner or user, ($2-$3) per day per container for the cost of CAMS and monitoring is far less expensive than the cost of CSI screening at a port (the current cost of CSI screening is passed on to the container user). CAMS was configured for quick pay back to the container owner’s ROI based on the value propositions and competitive advantages described herein, therefore, long term cost containment payback for CAMS also becomes a new revenue stream for the container lessor owner for the life of the container equipped with CAMS. The Company has had initial discussions with major retailers and the response was very positive and they agree that CAMS would benefit them. Insurance Companies endorsement will also be sought to reduce shipping costs when CAMS is installed in the shipping container, much like the use of anti-theft devices in cars and homes have reduced insurance premiums. The Company plans include a mass media (large advertising campaign) to inform our potential customers of the PRODUCT offering. Following and during the advertising campaign our Sales and Marketing staff will contact directly the major maritime shippers, the cargo container manufacturers, and major retailers, providing demonstrations. Part of sales strategy will include a customer incentive trial promotion and other similar promotions to attract and secure customers for our security and supply chain management products. As Quantum Leap moves forward, the company will be hiring a sales/marketing director with industry experience (maritime container and security devices). The company will participate in major trade shows and become a member of the Box Club and other maritime organizations. An advisory board related to marketing within the maritime commerce industry will be established and key industry individuals will be asked to be part of this advisory board. Through management’s key contacts in Washington DC, the company will lobby various US government departments in supporting and mandating the use of CAMS. The Company will review and evaluate distributors in each country and engage the best distributors per location, based on past history, sales, staffing, stability and financial soundness. Most distributors will be signed on as either non-exclusive or exclusive, with minimum annual sales volumes. Prospective customers who have expressed interest in CAMS, both solicited and unsolicited, include: DHL Ocean Secure (Germany), HCL Technologies (India), BCL Secure Premises (India), Temasek/Keppel (Singapore), Yang Ming Container (Taiwan), China Overseas Shipping Co. (China), Kuok Group (Malaysia), 36 Moller-Maersk (Norway), Mediterranean Shipping Co. (US office), D-Systems, SA (Greece), Stecans Imports (Canada) and Medusa Special Projects (US), among others. Competition With the launch of CAMS, we are confident that Quantum Leap will become the leader in the maritime container security and supply chain management device market. We have previously announced that CAMS has actually redefined the paradigm for an Advanced Container Security Device (ACSD) as defined by the U.S. Department of Homeland Security (DHS). The security industry in which we are engaged is intensely competitive, however,Quantum Leap’s CAMS far surpasses any of the competition which includes well-known companies who produce the large monitoring systems that are installed in CSI-compliant ports; i.e., Unisys, GE, EV Products, Radiation Monitoring Devices, ORTEC, SAPYHMO, RFTrax, RAE Systems, Rapiscan Systems, Lockheed Martin, BAE Systems, Aracor, American Science and Engineering, Savi, Bulldog Tech and others. Per information supplied by the U.S. Government, the majority of the above mentioned companies’ products are specifically RFID-based. While our products compete directly with RFID in various areas of our sector, and are RFID compliant, CAMS is not dependent on RFID and CAMS outperforms RFID. CAMS technology transcends and overlaps other market sectors currently being serviced by RFID as there was NO other available technology until CAMS. With CAMS, many benefits can be realized in the form of cost savings, cost containment, cost avoidance, and even as a source for new revenue stream; all together, a definite competitive advantage for the shipping container owner. With CAMS, the container owner can already meet many of the requirements of the Customs-Trade Partnership Against Terrorism (C-TPAT), without the requirement for additional personnel. C-TPAT is a voluntary public-private partnership program in which the private owners of supply chain infrastructure and cargo work with U.S. Customs and Border Protection to improve the security of the international supply chain. See www.cbp.gov for details. (source: http://ntl.bts.gov/lib/35000/35900/35956/Container_ports.pdf) The CAMS devicehas been endorsed by a recognized world trade organization as useful for detection of human trafficking. We have also been in discussions with major wireless communications companies as potential strategic partners and we have a comprehensive plan for installation of CAMS anywhere, worldwide. Competition for CONTAINER TRACKING ONLY CAMS does much, much more than just container tracking, so the market for CAMS is much broader than companies who specialize only in this particular section of the niche market. 4737 According to a new research report from the analyst firm Berg Insight1, the number of active remote container tracking units deployed on intermodal shipping containers was 77,000 in Q4-2011. Growing at a compound annual growth rate (CAGR) of 66.9 percent, this number is expected to reach 1.0 million by 2016. The penetration rate of remote tracking systems in the total population of containers is estimated to increase from 0.4 percent in 2011 to 3.6 percent in 2016. Berg Insight's definition of a real-time container tracking solution is a system that incorporates data logging, satellite positioning and data communication to a back-office application. The market for container tracking solutions is still in its early stage. Aftermarket solutions mounted on high value cargo and refrigerated containers will be the first use cases to adopt container tracking. Orbcomm has after recent acquisitions of Startrak and PAR LMS emerged as the largest vendor of wireless container tracking devices with solutions targeting refrigerated containers. Qualcomm, ID Systems and Telular are prominent vendors focusing on inland transportation in North America, which is so far the most mature market for container tracking solutions. PearTrack Systems, Honeywell Global Tracking, EPSa and Kirsen Global Security are examples of companies offering dedicated solutions targeting the global end-to-end container transport chain. Ever since the events of 9/11, there have been a lot of activities to bring container tracking solutions to the market, said Johan Svanberg, senior analyst, Berg Insight. Orbcomm (StarTrak, PAR LMS) "has after recent acquisitions of Startrak and PAR LMS emerged as the largest vendor of wireless container tracking devices with solutions targeting refrigerated containers" Orbcomm (StarTrak, PAR LMS) has NO proprietary technology on the M2M side; they are relying on COTS tech to fill that need. Orbcomm only does tracking (GPS and monitoring the location) with good financial results in that Orbcomm’s has Revenue: $40.14M, Gross Profit: $22.48M and an EBITDA: $5.36M. Some of the other companies mentioned in the Berg’s report which could be considered competitors of Quantum Leap Defense (for tracking only) are Agheera, AT&T, Avante International Technology, CargoTrax, CSB Technologies, Cubic Global Tracking Solutions, EPSa, FreightWatch, Global Tracking Technology, Hi-G-Tek, Honeywell Global Tracking, ID Systems - Asset Intelligence, Intelleflex, ITC Infotech, Johnson Controls, Kirsen Global Security, Logica, Mark-It Services, Masternaut, OnAsset Intelligence, Orbcomm (StarTrak, PAR LMS), PearTrack Systems, Pointer Telocation, Powers International, Qualcomm Enterprise Services, Savi Technology, Starcom Systems, System Planning Corporation, Telenor Traxion and Telular. None of these companies have all of the technology and/or all the capabilities of CAMS. For most of the competitors, their ocean going ability to track is nil due to the failure of the need for AIS system satellites! Most products provided by the above mentioned companies, are suited for users who send very small amounts of data. To avoid interference at terminals, these companies’ products are not permitted to be active more than 1% of the time, and thus they may only execute a 450ms data burst twice every 15 minutes. The latency inherent in Orbcomm’s network design prevents it from supporting certain safety-critical applications. 38 Currently Orbcomm (StarTrak, PAR LMS) is the leader in the reefer business because customers don't have any other choice, that is, until Quantum Leap launches CAMS. Orbcomm focus is on tractor trailers (reefers) and not maritime shipping containers. Orbcomm cannot be fitted on non-refrigerated shipping containers as the modem alone requires a minimum of 10.5v to transmit so their unit needs a 12v power supply which requires a lantern battery or car battery (large battery). Currently the refrigeration units on trucks offer the needed 12v power source. 1Reference: http://www.businesswire.com/news/home/20120215006498/en/Research-Markets Container-Tracking-Security---Installed. 39 Over $200MM in R &D contributions have been made as it relates to the development of the technologies underlying the CAMS devices; portions of which have been utilized by NASA and the US Department of Defense. As a result of the software and hardware firewalls implemented within the device, CAMS has no clearance issues as it relates to International Traffic in Arms Regulations ("ITAR"), allowing it to be used in civilian applications. Quantum leap Contact:Andrew Pritchard apritchard1963@gmail.com 40 Quantum Leap Ventures: Quantum Leap Ventures is structured to incubate ideas and enterprises inside and outside Quantum Leap. It is our goal to enable those by structuring the proper conditions for optimal development. Quantum Leap Analytics will bring many opportunities to us because of its breakthrough capabilities. Quantum Leap looks to assist the future. Those that work with us may choose to stay with Quantum Leap Companies or go out on their own. 41 Patents 42 Examples of Past Work Done 43 44 45 46

Executive Summary

Quantum Leap Innovations® DISCOVER PREDICT REASON Quantum Leap Companies General Use of Proceeds The Quantum Leap companies represent a family of technology companies fully owned by the Quantum Leap Holdings parent company with focus on both horizontal big data analytics opportunities as well as unique, vertical opportunities in high growth segments such as biomedicine, healthcare and the internet of things. In each segment a unique, highly competitive combination of big data analytics software and proprietary hardware platform is combined. The key to all offerings is best of breed solutions and products at an affordable pricing that will disrupt both horizontal and vertical markets in a major way. Total Funding Demand $10,000mm $720mm for Quantum Leap Analytics: Quantum Leap Analytics is building products based on the ADVANCED ANALYTICS PLATFORM that combines over a dozen years of R&D in areas of data management, descriptive and predictive analytics, multi-scale simulation and adaptive optimization. It includes software that would automatically scale over big data and is protected by variety of patents. The first product, the QUANTUM LEAP ANALYST, provides easy to learn and use functionality of manipulating data, finding relevant (to a question the user have) patterns in data, and obtaining predictions for future. It is currently focused on use of structured (that is pre organized) data but in the near future would also utilize unstructured (that is un- organized, from different sources, example Twitter or LinkedIn or collection of selected web sites where the data has to be extracted) data. Companion product to the QUANTUM LEAP ANALYST and one that is addressing even a larger market (potentially dozens of millions) is the QUANTUM LEAP BUZZ which is targeted at unstructured data and was released as a successful experiment for analyzing Twitter and Facebook data. The initial version of this product would focus on very fast startup and adoption as it needs no setup (unlike all of its competitors) as to domain knowledge and language. $700mm for Quantum Leap Bio: Quantum Leap Bio combines its GENOMIC DISCOVERY PLATFORM with the QUANTUM LEAP ANALYST to allow quick and affordable discovery of genes that are involved in different phases of a disease (initially cancer), for an individual in various stages of her/his disease and then these genes can be used by the company's THERAPEUTIC DEVELOPMENT & PRODUCTION PLATFORM to create individualized immunotherapy that would potentially adjust dynamically to the change in the disease itself (for example, cancer cells would genetically evolve to try and counter act a treatment protocol). What we envision is a "factory for the creation of individualized therapeutics" for major diseases which would be affordable and could be expanded to treat most individuals and provide the opportunity for major acceleration of the adoption of precision/personalized medicine. 1 Quantum Leap Innovations® DISCOVER PREDICT REASON $890mm for Quantum Leap Defense: Quantum Leap Defense's MOLECULAR DIAGNOSTICS PLATFORM is the ultimate sniffer, or what some call an "artificial nose". Competing efforts to create an artificial nose are too specialized and complex vs. this unique, proprietary technology platform. As an example, one immediate application of this platform is its placement in shipping containers to provide on-going and accurate account of what is being shipped including dangerous chemicals and biological materials, radioactive materials, etc. This is a crucial application as to the spread of extreme terrorism around the world; plus, one that could also provide for a counter to drug and human smuggling. Ultimately, the MOLECULAR DIAGNOSTICS PLATFORM can be used to sense and detect (utilizing our ADVANCED ANALYTICS PLATFORM) vulnerable modes of public transportation, including planes and trains, public facilities such as schools, sporting venues, shopping malls, as well as protection of critical infrastructure including key bridges, tunnels and more. $690mm for Quantum Leap Ventures: Due to the disruptive analytical capabilities of Quantum Leap there will be many opportunities that will present themselves from inside and outside Quantum Leap as different experts in their fields gain knowledge. Quantum Leap will help incubate and promote these efforts to further strengthen the Quantum Leap name in the market place. This will only happen if all parties find it mutually beneficial to all involved. $7,000mm for Quantum Leap Companies Year 2 2 QL - Requirements 3.1.19 Color Key: Quantum Leap Analytics Quantum Leap Bio Quantum Leap Defense Quantum Leap Ventures Funding -2 before 90 days Funding - 3 before 120 days in $ to Դ UT in in Grand Total before 120 days 9,000,000 180,000,000 22,000,000 220,500,000 280,500,000 5,000,000 10,000,000 11,500,000 1,500,000 210,000,000 day 1 Funding - 1 before 30 days ACQUISITION before 45 days Housekeeping Analytics QU to 9,000,000 $ - $ 10,000,000 $ 20,000,000 to in 150,000,000 $ 1,000,000 $ 4,000,000 17,000,000 to QLBio 500,000 $ 5,000,000 fee $ 65,000,000 QLD Canada 500,000 $ 5,000,000 fee $ 75,000,000 n 150,000,000 200,000,000 to 500,000 $ 500,000 $ 4,000,000 WOOD Italy QLX " 500,000 $ 9,500,000 $ 500,000 $ 11,000,000 to in $ 1,500,000 QLV 500,000 $ 9,500,000 $ $ 200,000,000 Funding - 1 $ 23,000,000 $ 55,000,000 $ 172,000,000 $ 250,000,000 Funding - 2 $ 700,000,000 Funding - 3 (platform) TOTAL $ 2,050,000,000 $ 2,050,000,000 $3,000,000,000 YEAR 2 $7,000,000,000 Direct and Ancillary Employment (All cells in can be changed) Hiring Rates ASSUMPTIONS: year 2-7 year 8-12 year 13-15 QL ANALYTICS 100% 20% 10% QL BIO 100% 20% 10% QL DEFENSE 90% 10% 5% QL VENTURES 50% 40% 20% START END YEAR END YEAR END YEAR END YEAR END YEAR END YEAR END YEAR END YEAR 1 2 3 QL ANALYTICS 250 2,000 4,000 8,000 4 16,000 5 32,000 6 64,000 7 128,000 8 END YEAR 9 153,600 184,320 END YEAR END YEAR 10 221,184 11 END YEAR 12 END YEAR END YEAR END YEAR 13 14 265,421 318,505 350,355 385,391 15 423,930 QL BIO 250 2,000 4,000 8,000 16,000 32,000 64,000 128,000 153,600 184,320 221,184 265,421 318,505 350,355 385,391 423,930 QL DEFENSE 4,000 8,000 15,200 28,880 54,872 104,257 198,088 376,367 414,004 455,404 500,945 551,039 606,143 636,450 668,273 701,686 QL VENTURES 500 20,000 30,000 45,000 67,500 101,250 151,875 227,813 318,938 446,513 625,118 875,165 1,225,230 1,470,276 1,764,332 2,117,198 Total 5,000 32,000 53,200 89,880 154,372 269,507 477,963 860,180 1,040,141 1,270,557 1,568,430 1,957,045 2,468,383 2,807,437 3,203,386 3,666,744 ANCILLARY EMPLOYMENT ASSUMPTION: Emploment Multiplier: 2 START END YEAR END YEAR END YEAR END YEAR END YEAR END YEAR END YEAR END YEAR END YEAR 2 3 4 5 6 7 8 9 END YEAR END YEAR END YEAR 10 11 12 END YEAR 13 END YEAR END YEAR 14 15 Total 0 64,000 106,400 179,760 308,744 539,014 955,926 1,720,359 2,080,283 2,541,113 3,136,860 3,914,090 4,936,766 5,614,875 6,406,772 7,333,489 GRAND TOTAL 5,000 96,000 159,600 269,640 463,116 808,520 1,433,889 2,580,539 3,120,424 3,811,670 4,705,290 5,871,135 7,405,149 8,422,312 9,610,159 11,000,233 Employment Examples: Samsung 320,000 IBM 366,000 Verizon 144,000 Johnson & Johnson 134,000 Wells Fargo 258,000 Shipping Industry 1,200,000 Printing Industry 600,000 University Research 720,000

Funds Required